- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07813351
PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours (PRESTO)
The goal of this clinical trial is to evaluate whether a higher dose of radiotherapy can lead to better outcomes for participants with functioning pituitary tumours. The main question it aims to answer is whether a greater proportion of participants will achieve normal hormone levels with the higher dose of proton beam radiotherapy than with standard radiotherapy treatment doses.
Following randomisation, participants will receive approximately 6 weeks of either standard dose radiotherapy (intensity-modulated radiation therapy or proton beam therapy, depending on age) OR escalated dose proton beam therapy. Following this, participants will be followed up for at least 2 years to monitor their condition. This includes pituitary, hormone level, tumour, neurocognitive, and ophthalmology assessments, as well as patient-reported quality of life outcomes and health economic measures.
Aperçu de l'étude
Statut
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: PRESTO Trial Manager
- Numéro de téléphone: +44 (0)20 7679 9860
- E-mail: ctc.presto@ucl.ac.uk
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Neuropathological confirmation of growth hormone (acromegaly) or ACTH (Cushing's disease) secreting pituitary adenoma after neurosurgical intervention.
- Ongoing hormonal hypersecretion as defined by local and age-specific normal range values without hormone supressing medication (may need washout).
- Multidisciplinary team meeting recommendation for fractionated radiotherapy.
- Karnofsky performance status ≥70.
- Age ≥18 years.
- Agreement to travel to a proton beam therapy centre (i.e. UCLH or The Christie) as required.
- Written informed consent.
- Agreement to be followed up at a local PRESTO trial site.
Exclusion Criteria:
- Women who are pregnant or breast feeding.
- Prior cranial or head and neck radiotherapy treatment, including Stereotactic radiosurgery (SRS).
- Unsuitability or intolerability of MRI scans.
- Severe active comorbidities that limit compliance with trial requirements.
- Prior invasive malignancy unless disease free interval of ≥3 years.
- Unable to travel to the PBT centres as per trial requirements.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Standard dose radiotherapy
Standard dose: 1.8Gy per fraction over 28 fractions.
|
Standard dose IMRT (1.8Gy per fraction) Standard dose PBT (1.8Gy per fraction) |
|
Expérimental: Escalated dose proton beam therapy
Escalated dose: 2Gy per fraction over 28 fractions. - Participants will receive escalated dose Proton Beam Therapy (PBT). |
Escalated dose PBT (2Gy per fraction) |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to normalisation of hormone levels
Délai: From randomisation until normalisation (occurring within 2 years after completion of treatment).
|
Time to normalisation of hormone levels (i.e. growth hormone (GH) or insulin growth factor 1 (IGF-1)) following randomised treatment |
From randomisation until normalisation (occurring within 2 years after completion of treatment).
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Neurocognitive function and Neuro-ophthalmology outcomes
Délai: From randomisation until 24 months after completion of treatment
|
From randomisation until 24 months after completion of treatment
|
|
|
Radiological treatment response
Délai: From baseline until 24 months after completion of treatment.
|
Data from MRI scans assessed for rates of stability, regression, and. progression. Overall response rate will be presented. |
From baseline until 24 months after completion of treatment.
|
|
Radiological progression-free survival (PFS)
Délai: From randomisation until progression (up to 2 years after completion of treatment) or death.
|
Progression-free survival (progression determined from an MRI scan). |
From randomisation until progression (up to 2 years after completion of treatment) or death.
|
|
Medical therapies for hormone excess
Délai: From randomisation to completion of trial participation (2 years after completion of treatment)
|
The number and proportion of participants requiring new/changes to medical therapy for hormone excess at each visit. |
From randomisation to completion of trial participation (2 years after completion of treatment)
|
|
Changes to hormone levels
Délai: From randomisation to completion of trial participation (2 years after completion of treatment)
|
Hormone levels relevant to the participant's disease (e.g. growth hormone [GH]) will be measured at each trial visit, summarised, and compared over time between treatment arms. |
From randomisation to completion of trial participation (2 years after completion of treatment)
|
|
Safety and toxicity
Délai: Between randomisation and 6 months after completion of treatment for early toxicities, and until 2 years after completion of treatment for late toxicities.
|
Adverse events, assessed by CTCAE criteria v6.0. |
Between randomisation and 6 months after completion of treatment for early toxicities, and until 2 years after completion of treatment for late toxicities.
|
|
Quality of life (CushingQoL/AcroQoL)
Délai: From baseline until 24 months post completion of treatment.
|
Quality of life (QoL) using either the CushingQoL/AcroQoL (as applicable depending on participant's condition) questionnaire. |
From baseline until 24 months post completion of treatment.
|
|
Quality of Life (EQ-5D-5L)
Délai: From baseline until 24 months post completion of treatment.
|
Quality of Life (QoL) using results of participant-reported EQ-5D-5L questionnaires. |
From baseline until 24 months post completion of treatment.
|
|
Pituitary insufficiency rates
Délai: From baseline until 24 months after completion of treatment.
|
Pituitary insufficiency rates (i.e. Growth hormone (GH), Adrenocorticotropic hormone (ACTH), Thyroid-Stimulating Hormone (TSH), Gonadotrophin, and Arginine Vasopressin (AVP) deficiencies) will be summarised and compared between arms. |
From baseline until 24 months after completion of treatment.
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Health Economic Evaluation
Délai: From 6 months prior to baseline until 2 years after completion of trial treatment.
|
The health economic analysis will calculate the mean incremental cost per quality-adjusted life-years (QALYs) gained on using dose-escalated proton beam therapy compared to standard dose radiotherapy. |
From 6 months prior to baseline until 2 years after completion of trial treatment.
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Michael Kosmin, UCLH NHS Trust
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système endocrinien
- Maladies osseuses
- Maladies musculo-squelettiques
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Tumeurs par site
- Tumeurs
- Tumeurs par type histologique
- Tumeurs des glandes endocrines
- Tumeurs, glandulaires et épithéliales
- Tumeurs du système nerveux
- Tumeurs du système nerveux central
- Maladies hypothalamiques
- Tumeurs hypothalamiques
- Tumeurs supratentorielles
- Tumeurs cérébrales
- Hyperpituitarisme
- Maladies osseuses, endocriniennes
- Adénome
- Tumeurs hypophysaires
- Maladies de l'hypophyse
- Hypersécrétion hypophysaire d'ACTH
- Acromégalie
- Adénome hypophysaire sécrétant l'hormone de croissance
- Thérapeutique
- Radiothérapie
- Radiothérapie, conforme
- Radiothérapie, assistée par ordinateur
- Radiothérapie à ions lourds
- Radiothérapie, intensité modulée
- Protonothérapie
Autres numéros d'identification d'étude
- UCL/181514
- NIHR168012 (Autre subvention/numéro de financement: National Institute for Health and Care Research (NIHR))
- 369251 (Autre identifiant: IRAS)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .